1-5 of 5
Paul M. Johannet
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mechanisms of Acquired Drug Resistance to the Isoform Selective HDAC6 Inhibitor Ricolinostat Reveals Markedly Upregulated Elements of the BTK Pathway Revealing Rational Drug : Drug Combinations

Jennifer E Amengual, MD, Maximilian Lombardo, Kelly M Zullo, Paul M. Johannet, BA, Sathyen A Prabhu, Gonzalez Yulissa, Luigi Scotto, PhD, Ying Wei, Jimmy Duong, Owen A. O'Connor, MD PhD
Journal: Blood
Blood (2015) 126 (23): 3708.
https://doi.org/10.1182/blood.V126.23.3708.3708
Published: 2015
Journal Articles

Development and Characterization of Two Lymphoma Cell Lines Resistant to the Selective HDAC6 Inhibitor Ricolinostat (ACY-1215) As a Tool to Better Understand the Biology of HDACs on Lymphoma

Jennifer E Amengual, MD, Paul M. Johannet, BA, Kelly Zullo, MS, Maximilian Lombardo, MS, Owen A. O'Connor, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1777.
https://doi.org/10.1182/blood.V124.21.1777.1777
Published: 2014
Journal Articles

Dual Targeting With The Selective Histone Deacetylase (HDAC) 6 Inhibitor, ACY-1215, and Bortezomib (BOR) Leads To Marked Disruption Of Protein Degradation Pathways and Apoptosis In Preclinical Models Of Lymphoma

Jennifer E. Amengual, MD, Paul M Johannet, Xavier Jirau-Serrano, BS, Kelly Zullo, BS, Daniela Hoehn, MD, PhD, Govind Bhagat, MD, Maximilian Lombardo, B.S., Luigi Scotto, PhD, Simon S Jones, PhD, Owen A. O'Connor, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 648.
https://doi.org/10.1182/blood.V122.21.648.648
Published: 2013
Journal Articles

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor Rocilinostat (ACY-1215) and Bortezomib, Demonstrates Synergistic Antitumor Activity in Preclinical Models of Lymphoma

Jennifer E Amengual, MD, Paul M Johannet, Simon S Jones, Owen A. O'Connor, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1650.
https://doi.org/10.1182/blood.V120.21.1650.1650
Published: 2012
Journal Articles

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

Jennifer E Amengual, MD, Sean Clark-Garvey, Matko Kalac, MD, PhD, Luigi Scotto, PhD, Enrica Marchi, MD, PhD, Celests Rojas, Ellen Neylon, FNP, MSN, RN, OCN, Paul M Johannet, Salvia Jain, MD, Jasmine M. Zain, MD, Owen A. O'Connor, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 2725.
https://doi.org/10.1182/blood.V120.21.2725.2725
Published: 2012